Author:
Kamb Alexander,Wee Susan,Lengauer Christoph
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference33 articles.
1. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).
2. Roberts, T. G. Jr et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292, 2130–2140 (2004).
3. Mortlock, A. A. et al. Progress in the development of selective inhibitors of aurora kinases. Curr. Top. Med. Chem. 5, 807–821 (2005).
4. Ruetz, S., Fabbro, D., Zimmermann, J., Meyer, T. & Gray, N. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. Curr. Med. Chem. Anti-Canc. Agents 3, 1–14 (2003).
5. Aghajanian, C. et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2502–2511 (2002).
Cited by
295 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献